RCUS vs. ANIP, KURA, MORF, AKRO, DAWN, GYRE, EWTX, ARDX, ZLAB, and IRWD
Should you be buying Arcus Biosciences stock or one of its competitors? The main competitors of Arcus Biosciences include ANI Pharmaceuticals (ANIP), Kura Oncology (KURA), Morphic (MORF), Akero Therapeutics (AKRO), Day One Biopharmaceuticals (DAWN), Gyre Therapeutics (GYRE), Edgewise Therapeutics (EWTX), Ardelyx (ARDX), Zai Lab (ZLAB), and Ironwood Pharmaceuticals (IRWD). These companies are all part of the "pharmaceutical preparations" industry.
ANI Pharmaceuticals (NASDAQ:ANIP) and Arcus Biosciences (NYSE:RCUS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.
ANI Pharmaceuticals currently has a consensus target price of $80.00, suggesting a potential upside of 23.17%. Arcus Biosciences has a consensus target price of $41.25, suggesting a potential upside of 180.04%. Given ANI Pharmaceuticals' higher probable upside, analysts clearly believe Arcus Biosciences is more favorable than ANI Pharmaceuticals.
ANI Pharmaceuticals has higher revenue and earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 12.7% of ANI Pharmaceuticals shares are owned by insiders. Comparatively, 13.8% of Arcus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
ANI Pharmaceuticals has a net margin of 3.86% compared to ANI Pharmaceuticals' net margin of -262.39%. Arcus Biosciences' return on equity of 18.06% beat ANI Pharmaceuticals' return on equity.
In the previous week, ANI Pharmaceuticals had 9 more articles in the media than Arcus Biosciences. MarketBeat recorded 13 mentions for ANI Pharmaceuticals and 4 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 0.44 beat ANI Pharmaceuticals' score of 0.14 indicating that ANI Pharmaceuticals is being referred to more favorably in the media.
ANI Pharmaceuticals has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500.
ANI Pharmaceuticals received 244 more outperform votes than Arcus Biosciences when rated by MarketBeat users. Likewise, 64.59% of users gave ANI Pharmaceuticals an outperform vote while only 64.41% of users gave Arcus Biosciences an outperform vote.
Summary
ANI Pharmaceuticals beats Arcus Biosciences on 12 of the 18 factors compared between the two stocks.
Get Arcus Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RCUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arcus Biosciences Competitors List
Related Companies and Tools
